Organization of Gaucher disease management in France

Gaucher disease management in France is facilitated by CETG (Comitee of Evaluation and Treatment of Gaucher disease). Four hundred and fifty-six patients are enrolled in 2006 in the French Gaucher registry of CETG. Two hundred and thirty patients had treatment. Eighty five % are type 1, 10.5% type 2...

Full description

Saved in:
Bibliographic Details
Published inLa revue de medecine interne Vol. 28 Suppl 2; p. S198
Main Authors Stirnemann, J, de Villemeur, T Billette, Belmatoug, N
Format Journal Article
LanguageFrench
Published France 01.10.2007
Subjects
1-Deoxynojirimycin - analogs & derivatives
1-Deoxynojirimycin - therapeutic use
Adolescent
Adult
Aged
Child
Child, Preschool
Enzyme Inhibitors - therapeutic use
Female
France - epidemiology
Gaucher Disease - complications
Gaucher Disease - drug therapy
Gaucher Disease - epidemiology
Gaucher Disease - genetics
Gaucher Disease - therapy
Glucosylceramidase - therapeutic use
Hospitalization
Humans
Infant
Infant, Newborn
Male
Middle Aged
Parkinsonian Disorders - complications
Registries
Saposins - deficiency
Treatment Outcome
Online AccessGet full text

Cover

More Information
Summary:Gaucher disease management in France is facilitated by CETG (Comitee of Evaluation and Treatment of Gaucher disease). Four hundred and fifty-six patients are enrolled in 2006 in the French Gaucher registry of CETG. Two hundred and thirty patients had treatment. Eighty five % are type 1, 10.5% type 2 and 5.5% type 3. Only 1 patient had a saposin C deficiency. Information on CETG is available on www.cetl.net.
ISSN:0248-8663